DEFA14A: Repare Sells RP-3467 Program to Gilead for $30M, Boosts Shareholder Payout

Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences for its RP-3467 program, generating up to $30 million and increasing the estimated cash payout to shareholders in its pending acquisition by Xeno.

Summary

• Repare Therapeutics Inc. (Repare) has sold its RP-3467 program, a polymerase theta (Pol) ATPase inhibitor in Phase 1 clinical development for advanced solid tumors, to Gilead Sciences, Inc. (Gilead).
• The total purchase price is up to $30,000,000 in cash, comprising a $22,000,000 upfront payment, a $3,000,000 holdback, and a $5,000,000 payment upon transfer completion.
• This asset sale has increased Repare's cash balance, consequently raising the estimated cash payment to shareholders in the pending acquisition by XenoTherapeutics, Inc. to approximately US$2.20 per common share.
• The RP-3467 program assets transferred include intellectual property, materials, records, regulatory documents, and licenses, but explicitly exclude other Repare programs (RP-1664, lunresertib/camonsertib), employee contracts, cash, accounts receivable, real property, and equipment.
• Repare also secured a consent to assignment from New York University for a license agreement related to RP-3467, involving a one-time payment of $250,000 to NYU.

Sentiment

Score: 8

Explanation: The asset sale to Gilead Sciences for up to $30 million, particularly the $22 million upfront payment, significantly boosts Repare's cash position. This directly translates to a higher estimated payout for shareholders in the upcoming Xeno acquisition, increasing it to US$2.20 per share. This provides a clear, tangible benefit to shareholders and de-risks the company's financial standing ahead of its acquisition, despite divesting a clinical-stage asset.

Positives

• Secured up to $30,000,000 in cash from Gilead Sciences for the RP-3467 program, providing significant capital.
• The upfront payment of $22,000,000 has increased Repare's cash balance, directly boosting the estimated cash payout to shareholders in the upcoming Xeno acquisition to approximately US$2.20 per common share.
• The transaction is described by management as the 'third and most significant portfolio transaction for Repare this year,' indicating successful strategic asset management.
• The sale allows Repare to streamline its focus on other programs like RP-1664 and lunresertib/camonsertib, as these assets were explicitly excluded from the sale.

Negatives

• Divestment of a clinical-stage asset (RP-3467) means Repare will no longer benefit from its potential future success or commercialization.
• The holdback amount of up to $3,000,000 and the $5,000,000 transfer completion payment are contingent, not guaranteed immediately.

Risks

• The consummation of the Asset Sale and the anticipated benefits thereof are subject to various known and unknown risks and uncertainties.
• Actual results, performance, or achievements may differ materially from forward-looking statements due to factors beyond control or prediction.
• Risks identified in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, are still applicable.
• The ability to successfully pursue a strategic transaction on attractive terms, or at all, is a risk.
• Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate efficacy and safety of a product candidate.
• Impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the company's business, clinical trials and financial position.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
• Clinical trial site activation or enrollment rates that are lower than expected.
• The company's ability to realize the benefits of its collaboration and license agreements.
• Changes in expected or existing competition.
• Changes in the regulatory environment and the uncertainties and timing of the regulatory approval process.
• Unexpected litigation or other disputes.

Future Outlook

Repare Therapeutics expects to receive the remaining contingent payments from Gilead Sciences upon successful completion of the transfer plan. The upfront payment from the asset sale has increased the estimated cash payout to shareholders in the pending Xeno acquisition to approximately US$2.20 per common share. The company continues to focus on its proprietary synthetic lethality approach for novel therapeutics, including other programs like RP-1664 and lunresertib/camonsertib.

Management Comments

• "Pleased to announce this transaction which combines Gileads leading expertise in oncology research and development with RP-3467, a potential best-in-class Pol ATPase inhibitor."
• "This marks the third and most significant portfolio transaction for Repare this year."

Industry Context

The divestment of a clinical-stage oncology asset to a major pharmaceutical company like Gilead Sciences highlights the ongoing trend of larger players acquiring promising early-stage programs to bolster their pipelines. For Repare, a precision oncology company, this transaction provides immediate capital and potentially validates its synthetic lethality platform, while allowing it to re-focus resources on its remaining pipeline assets. The sale of RP-3467, a Pol ATPase inhibitor, to Gilead, a company with significant oncology R&D expertise, suggests a strategic fit for both parties, with Gilead gaining a potential best-in-class asset and Repare securing funds ahead of its own acquisition by XenoTherapeutics.

Stakeholder Impact

• Shareholders: Expected to receive a higher cash payment (estimated US$2.20 per share) in the pending Xeno acquisition due to the increased cash balance from the asset sale.
• Employees: Employee contracts were explicitly excluded from the asset sale, indicating no direct impact on employment relationships from this specific transaction.
• Customers/Patients: The RP-3467 program will continue under Gilead Sciences, potentially benefiting from Gilead's expertise and resources for further development.
• New York University: Received a one-time payment of $250,000 for consenting to the license assignment.

Next Steps

• Gilead to pay $22,000,000 to Repare by December 31, 2025.
• Repare and Gilead to complete the transfer plan for the RP-3467 program assets, leading to a $5,000,000 payment upon successful completion.
• Repare to receive the holdback amount of up to $3,000,000 after one year, subject to terms.
• Repare to make a one-time payment of $250,000 to New York University within 30 days of the effective time of the Sale Transaction.
• Special meeting of Repare shareholders to be held on January 16, 2026, to approve the Xeno acquisition.
• Repare to cooperate with Purchaser to transition sponsorship of the RP-3467 Clinical Trial to Purchaser, including transferring the relevant IND.
• Repare to continue timely submission of all Regulatory Documents for RP-3467 IND until fully transferred to Purchaser.

Key Dates

Recommendation

The asset sale to Gilead Sciences for up to $30 million has directly increased the estimated cash payout to Repare shareholders in the pending Xeno acquisition to approximately US$2.20 per common share. For existing shareholders, this represents a tangible increase in their expected return from the acquisition. For investors considering an arbitrage opportunity, if the stock is trading below this revised estimated payout, it presents a clear 'buy' signal to capture the increased value, assuming the Xeno acquisition proceeds as planned. The transaction de-risks the company's financial position ahead of the acquisition and provides a favorable outcome for shareholders.

Keywords

Repare Therapeutics, Gilead Sciences, Asset Purchase Agreement, RP-3467, Polymerase Theta Inhibitor, Oncology, Clinical-stage, Synthetic Lethality, BRCA mutations, XenoTherapeutics, Acquisition, Shareholder Payout, Biotechnology, Pharmaceuticals, Cancer Therapy, Form 8-K, POLAR Phase 1 trial